Semarion: University of Cambridge Spin-Out Raises $3.8 Million To Scale Cell Assay Technology For Drug Discovery
By Amit Chowdhry ● Yesterday at 11:44 PM
Semarion, a University of Cambridge spin-out focused on advancing cell-based research, announced it has raised $3.8 million to expand its next-generation cell assay technology and accelerate adoption across the pharmaceutical industry. The funding round was led by Parkwalk, with participation from The FSE Group, Cambridge Enterprise Ventures, Oxford Innovation Finance, Found Capital, Cambridge Capital Group, and Start Codon. The company said the new capital will support scaling manufacturing and commercial capacity for its SemaCyte platform.